Clinical trial to test recent findings that show LIXTE’s lead clinical compound,
LB-100, increases recognition of colon cancer cells by the immune system
June 14, 2024 -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer.
As part of the